345 related articles for article (PubMed ID: 8838120)
21. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
[TBL] [Abstract][Full Text] [Related]
22. [Wilms' tumour of unfavorable histology--results of treatment with the SIOP 93-01 protocol at the Gdańsk centre. Preliminary report].
Stefanowicz J; Sierota D; Balcerska A; Stoba C
Med Wieku Rozwoj; 2004; 8(2 Pt 1):197-200. PubMed ID: 15738594
[TBL] [Abstract][Full Text] [Related]
23. [Wilms' tumor (nephroblastoma) of the adult].
Alvaro Naranjo T; Algarra García R; Carazo Tirao A; Cueva Ruiz C
Actas Urol Esp; 1992 May; 16(5):426-9. PubMed ID: 1324564
[TBL] [Abstract][Full Text] [Related]
24. [Immunohistochemical expression of p53 oncoprotein in Wilms tumour in relation to histological components, histological types and preoperative chemotherapy].
Djuricić S; Djokić D; Vujić D; Basta-Jovanović G; Todorović V; Radojević-Skodrić S; Zdravković S; Vujanić GM
Srp Arh Celok Lek; 2008 Dec; 136 Suppl 4():298-306. PubMed ID: 20804099
[TBL] [Abstract][Full Text] [Related]
25. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations.
Bardeesy N; Beckwith JB; Pelletier J
Cancer Res; 1995 Jan; 55(2):215-9. PubMed ID: 7812946
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic utility of Wilms' tumour-1 protein (WT-1) immunostaining in paediatric renal tumours.
Goyal S; Mishra K; Sarkar U; Sharma S; Kumari A
Indian J Med Res; 2016 May; 143(Supplement):S59-S67. PubMed ID: 27748279
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of proliferating cell nuclear antigen in Wilms' tumour in children.
Skotnicka-Klonowicz G; Kobos J; Łoś E; Trejster E; Szymik-Kantorowicz S; Daszkiewicz P
Eur J Surg Oncol; 2002 Feb; 28(1):67-71. PubMed ID: 11869017
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical detection of p53 protein expression as a prognostic indicator in Wilms tumor.
Sredni ST; de Camargo B; Lopes LF; Teixeira R; Simpson A
Med Pediatr Oncol; 2001 Nov; 37(5):455-8. PubMed ID: 11745874
[TBL] [Abstract][Full Text] [Related]
29. Wilms' tumour as a paradigm for the relationship of cancer to development.
Pritchard-Jones K; Hastie ND
Cancer Surv; 1990; 9(3):555-78. PubMed ID: 1966278
[TBL] [Abstract][Full Text] [Related]
30. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
[TBL] [Abstract][Full Text] [Related]
31. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors.
Kaneko Y; Homma C; Maseki N; Sakurai M; Hata J
Cancer Res; 1991 Nov; 51(21):5937-42. PubMed ID: 1657374
[TBL] [Abstract][Full Text] [Related]
32. Aberrant expression of the tumour suppressor gene p53 is very frequent in Wilms' tumours.
Lemoine NR; Hughes CM; Cowell JK
J Pathol; 1992 Oct; 168(2):237-42. PubMed ID: 1334142
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-X(L) in rare tumor cases.
Re GG; Hazen-Martin DJ; El Bahtimi R; Brownlee NA; Willingham MC; Garvin AJ
Int J Cancer; 1999 Apr; 84(2):192-200. PubMed ID: 10096254
[TBL] [Abstract][Full Text] [Related]
34. Role of the WT1 gene in Wilms' tumour.
Haber DA; Housman DE
Cancer Surv; 1992; 12():105-17. PubMed ID: 1322241
[TBL] [Abstract][Full Text] [Related]
35. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S
Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629
[TBL] [Abstract][Full Text] [Related]
36. Responsiveness of chemotherapy based on the histological type and Wilms' tumor suppressor gene mutation in bilateral Wilms' tumor.
Shibata R; Takata A; Hashiguchi A; Umezawa A; Yamada T; Hata J
Pathol Int; 2003 Apr; 53(4):214-20. PubMed ID: 12675764
[TBL] [Abstract][Full Text] [Related]
37. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.
Natrajan R; Little SE; Sodha N; Reis-Filho JS; Mackay A; Fenwick K; Ashworth A; Perlman EJ; Dome JS; Grundy PE; Pritchard-Jones K; Jones C
J Pathol; 2007 Jan; 211(1):52-9. PubMed ID: 17103382
[TBL] [Abstract][Full Text] [Related]
38. Anaplastic histology Wilms' tumors registered to the Japan Wilms' Tumor Study Group are less aggressive than that in the National Wilms' Tumor Study 5.
Oue T; Koshinaga T; Takimoto T; Okita H; Tanaka Y; Nozaki M; Haruta M; Kaneko Y; Fukuzawa M;
Pediatr Surg Int; 2016 Sep; 32(9):851-5. PubMed ID: 27473009
[TBL] [Abstract][Full Text] [Related]
39. Expression and localization of HGF and met in Wilms' tumours.
Alami J; Williams BR; Yeger H
J Pathol; 2002 Jan; 196(1):76-84. PubMed ID: 11748645
[TBL] [Abstract][Full Text] [Related]
40. Splicing of exon 5 in the WT1 gene is disrupted in Wilms' tumour.
Simms LA; Algar EM; Smith PJ
Eur J Cancer; 1995 Dec; 31A(13-14):2270-6. PubMed ID: 8652255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
